15 December - The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic® (semaglutide).
“We are very excited about the positive opinion for Ozempic® for treatment of people with type 2 diabetes in Europe, many of whom are still looking for new and more efficacious solutions to better manage their disease,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “We believe Ozempic®, with its unique clinical profile, has the potential to set a new standard for treatment of type 2 diabetes.”
Ozempic® was recently approved by the US Food and Drug Administration and is currently under review by several regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency.
10 November - It’s been 12 months since Novo Nordisk made the difficult decision to discontinue its oral insulin development programme. Chief Science Officer Mads Krogsgaard Thomsen reflects on a year of learning, on what motivates him and his team and on the possibility to one day revisit the potential of oral insulin.
26 October - Cases of diabetes are accelerating in every part of the world meaning that today, one in 11 adults live with the condition.1 The report – Bending the Curve on Urban Diabetes – urges governments, city and health leaders to make changing the trajectory of the disease a top global priority in order to ‘bend the rising curve’ of diabetes prevalence.
An international coalition of cities is calling for an ambitious global goal to prevent more than 100 million new cases of diabetes by 2045; new research published in a report by the Cities Changing Diabetes partnership is launched today at a global summit in Houston, Texas. The report comes with the stark warning that achieving the goal requires cutting rates of obesity by a quarter.
With millions displaced by war, business has a key role in helping refugees integrate, contribute and flourish in society. Each individual you meet has their own personal backstory of despair and upheaval. Days on end spent on an over-crowded boat, bobbing on the Mediterranean. Families fragmented and dispersed. Careers and livelihoods abruptly curtailed.
Imagine that you perceive the noise level in the canteen as 100 times louder, and that even minor changes in your daily life cause you to lose your overview. Such is life for 28-year-old Louise Wille, who has Asperger’s and ADHD.
Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.
Contribution to a national life science strategy in Denmark from Novo Nordisk, Lundbeck and LEO Pharma.
Download the pdf
Get an instant impression of what Novo Nordisk is about, see the numbers and read about partnership activities that drive change.